Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Hao Wang, Gurbakhash Kaur, Alexander I. Sankin, Fuxiang Chen, Fangxia Guan, Xingxing Zang

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic malignancies. Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets. Here, we review the preclinical and clinical advances of CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy in hematologic malignancies. We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies.

Original languageEnglish (US)
Article number59
JournalJournal of Hematology and Oncology
Volume12
Issue number1
DOIs
StatePublished - Jun 11 2019

Fingerprint

Antigen Receptors
Hematologic Neoplasms
Cell- and Tissue-Based Therapy
Galectins
Immune System
Monoclonal Antibodies
Clinical Trials
T-Lymphocytes
Therapeutics
Research
Neoplasms

Keywords

  • CAR-T
  • CTLA-4
  • Hematologic malignancies
  • Immune checkpoints
  • Immunotherapy
  • New targets
  • PD-1

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. / Wang, Hao; Kaur, Gurbakhash; Sankin, Alexander I.; Chen, Fuxiang; Guan, Fangxia; Zang, Xingxing.

In: Journal of Hematology and Oncology, Vol. 12, No. 1, 59, 11.06.2019.

Research output: Contribution to journalReview article

@article{c6e6c57bfe684b8cb0d08cfe980a5790,
title = "Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies",
abstract = "Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic malignancies. Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets. Here, we review the preclinical and clinical advances of CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy in hematologic malignancies. We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies.",
keywords = "CAR-T, CTLA-4, Hematologic malignancies, Immune checkpoints, Immunotherapy, New targets, PD-1",
author = "Hao Wang and Gurbakhash Kaur and Sankin, {Alexander I.} and Fuxiang Chen and Fangxia Guan and Xingxing Zang",
year = "2019",
month = "6",
day = "11",
doi = "10.1186/s13045-019-0746-1",
language = "English (US)",
volume = "12",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

AU - Wang, Hao

AU - Kaur, Gurbakhash

AU - Sankin, Alexander I.

AU - Chen, Fuxiang

AU - Guan, Fangxia

AU - Zang, Xingxing

PY - 2019/6/11

Y1 - 2019/6/11

N2 - Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic malignancies. Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets. Here, we review the preclinical and clinical advances of CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy in hematologic malignancies. We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies.

AB - Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic malignancies. Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets. Here, we review the preclinical and clinical advances of CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy in hematologic malignancies. We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies.

KW - CAR-T

KW - CTLA-4

KW - Hematologic malignancies

KW - Immune checkpoints

KW - Immunotherapy

KW - New targets

KW - PD-1

UR - http://www.scopus.com/inward/record.url?scp=85067196824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067196824&partnerID=8YFLogxK

U2 - 10.1186/s13045-019-0746-1

DO - 10.1186/s13045-019-0746-1

M3 - Review article

C2 - 31186046

AN - SCOPUS:85067196824

VL - 12

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 59

ER -